One technology. Multiple applications.
A platform positioned between established categories, built to move up the evidence ladder over the coming decade.
- LAYER 01
Nutraceuticals
Everyday nutrition and functional formats.
- LAYER 02
Botanical Medical Foods
Standardised bioactive compositions.
- LAYER 03
Botanical Medical Drugs
Regulated therapeutic candidates
- LAYER 04
Future Medicines
Long horizon therapeutic development.
- LAYER 05
Innovative Platforms
Novel delivery formats and technology extensions.
Five directions from a single technology base.
Cardiovascular Health
Vascular function is the first area of focus and the clearest route to independent evaluation.
Metabolic Health
Cardiometabolic pathways where inflammatory and vascular biology intersect.
Healthy Ageing
Healthspan applications built on mechanisms shared across diseases of ageing particularly Neurodegenerative Models.
Scientific Partnerships
Joint research programmes with universities, institutes and clinical academics.
Global Licensing
Territory, category and format licensing to ingredient, food and pharmaceutical partners.
From food delivered bioactives to botanical therapeutics.
Neurogenics is developing a pipeline of botanical candidates across food delivered health, medical nutrition and botanical drug applications.
- CANDIDATE 01250 mg of flavanols
NC-OX1
Botanical antioxidant complex for oxidative stress reduction
- Cocoa-derived polyphenol matrix
- Targets endothelial oxidative load
- Supports vascular function
- Food-delivery compatible
- High stability and bioavailability
- CANDIDATE 02500 mg of flavanols
NC-CardioBlend
Multi-botanical formulation for cardiometabolic support
- Cocoa + plant peptides
- Improves metabolic signalling
- Reduces inflammatory stress
- Designed for daily consumption
- Early clinical feasibility underway
- Regulatory pathway to be agreed
- CANDIDATE 03PRECLINICAL
NC-DrugX
Next-generation botanical drug targeting oxidative stress pathways
- High-potency botanical extract
- Drug-like pharmacokinetics
- Cardiovascular and metabolic indications
- Developed under botanical drug regulatory pathway
- Preclinical development stage
Pipeline progression
- STAGE 01
Botanical Medical Food
- STAGE 02
Botanical Medical Food/Drug
- STAGE 03
Botanical Drug
Why does this matter?
Single-product companies are constrained by one indication. A characterised platform technology can support multiple applications and multiple partners simultaneously.
Why now?
Global ingredient, food and pharmaceutical companies are actively seeking defensible, evidence-backed natural bioactives with credible supply routes.
Why Neurogenics?
Protected process technology, a platform architecture from the outset, and a UK industrial biotechnology base built for scale-up and export.
